You are here:

fluticasone furoate/vilanterol (Relvar Ellipta)

Advice

following a full submission:

fluticasone furoate/vilanterol (Relvar Ellipta®) is accepted for restricted use within NHS Scotland.

Indication under review: symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.

SMC restriction: in patients with severe COPD (FEV1 <50% predicted normal).

In a comparative, 12-week study there was no statistically significant difference between fluticasone furoate/vilanterol 92/22 micrograms and another inhaled corticosteroid/long acting beta agonist combination inhaler for change from baseline trough in 24-hour weighted-mean FEV1.

Fluticasone furoate/vilanterol is also licensed for the treatment of asthma.  SMC is due to issue advice for this indication in June 2014.
 

Drug Details

Drug Name: fluticasone furoate/vilanterol (Relvar Ellipta)
SMC Drug ID: 953/14
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Full submission
Status: Restricted
Date Advice Published: 7 April 2014

Back